

145.000 mm

210.000 mm



Panaflex Max Pain Relief Patch

Precautions During Pregnancy :

- Third Trimester:
 - Non-Steroidal Anti-Inflammatory Drug (NSAID) use in the third trimester of pregnancy is contraindicated due to the risks of premature closure of the ductus arteriosus and the potential to prolong parturition.
- First and Second Trimesters:
 - NSAID use in the first and second trimesters of pregnancy, particularly from the middle (approximately 20 weeks) to end of the second trimester of pregnancy, should be cautioned due to possible fetal renal dysfunction leading to oligohydramnios and, in some cases, neonatal renal impairment or failure.
 - Published studies and postmarketing reports show that maternal NSAID use at approximately 20 weeks gestation or later in pregnancy causes significant reduction in fetal urine production prior to reduction of amniotic fluid volume. A limited number of case reports show that some cases of neonatal renal dysfunction and renal impairment without oligohydramnios were irreversible, even after discontinuation of NSAIDs. These adverse outcomes are seen, on average, after days to weeks of treatment, although oligohydramnios has been infrequently reported as soon as 48 hours after NSAID initiation. Prolonged oligohydramnios could cause complications including limb contractures and delayed lung maturation. In some postmarketing cases of impaired neonatal renal function, invasive procedures such as exchange transfusion or dialysis were required.
 - NSAIDs should not be used during the first two trimesters of pregnancy unless the expected benefits to the mother outweigh the risks to the fetus. If after careful consideration of the benefit-risk, the use should be limited to the lowest effective dose and shortest duration possible. It is also recommended that ultrasound monitoring of amniotic fluid be considered if NSAIDs treatment extends beyond 48 hours and that NSAIDs treatment be discontinued if oligohydramnios occurs, followed by appropriate medical follow up.

Contraindications:

The third trimester of pregnancy, because of risks of premature closure of the ductus arteriosus, and prolonged parturition.

Trade marks are owned by or licensed to the Haleon group of companies. © 2022 Haleon group of companies or its licensor.

TECHNICAL INFORMATION

CUT	
AMENDMENTS	
1	NEW
2	
3	
DRAWING OWNER:	TRIDENT
MANUFACTURING SITE:	Interphil
DATE:	19/09/2022
LEAFLET	
PACK DIMENSIONS 145x210mm	
DRAWING NO: DL-leaflet 210mm x 145mm	V1 SCALE 1:1
APPROVED BY GSK: <input type="checkbox"/> YES <input checked="" type="checkbox"/> NO Technical Drawing created by Trident	

V1

Artwork Information Panel

HALEON

02 - Jan - 2024

Non Production Artwork

Production Artwork

Component No: AWP No:
PR-030197HKAA TR3080093/A

Total Number of Colours including Varnish & Foils: 1

Manufacturing Site:
Teh Seng

Approving Market:
Hong Kong

Technical Drawing No:
DL- leaflet 210mm x 145mm

Material Spec No:
NA

Body Text Size: 6.0pt
Smallest Text Size: 6.0pt

Electronic Verification Code:
N/A

Printer and User notes:

Studio Location: Asia

AIP_CHAMPS_2023_HALEON

210mm x 145mm

— 刀線 CUTLINE

PR-030197HKAA

10mm

10mm

145.000 mm

210.000 mm



必理絡特強滲透止痛貼

懷孕注意事項:

- 妊娠晚期:
 - 在妊娠晚期使用非類固醇消炎止痛藥是禁忌的，因為會出現動脈導管過早閉合的風險和延長分娩的可能性。
- 妊娠初期及中期:
 - 在妊娠初期和中期，特別是從妊娠中期(約20週)到妊娠中期尾段，應謹慎使用非類固醇消炎止痛藥，因為潛在胎兒腎功能不全引致羊水過少，及在某些情況下，出現新生兒腎功能損害或衰竭。
 - 已發表的研究和上市後報告顯示，在妊娠約20週或以後，使用非類固醇消炎止痛藥會導致胎兒尿液生產顯著減少及羊水體積減少。有限數量的病例報告顯示，即使在停用非類固醇消炎止痛藥之後，一些新生兒在無羊水過少的腎功能不全和腎功能損害是不可逆轉的。這些不良結果平均在治療數天至數週後可見，儘管羊水過少很少在開始使用非類固醇消炎止痛藥後最早48小時匯報。長期羊水過少可引起併發症，包括肢體攣縮和肺成熟延遲。一些新生兒腎功能損害的上市後病例需要進行侵入性程序，例如換血或透析。
 - 非類固醇消炎止痛藥不應在妊娠初期及中期使用，除非對母親的預期益處大於對胎兒的風險。如果在詳細評估獲益及風險後，應盡可能使用最低的有效劑量及最短的持續時間。如果非類固醇消炎止痛藥治療超過48小時，建議考慮使用超聲波對羊水進行監測，如果出現羊水過少的情況，停止非類固醇消炎止痛藥治療，並進行適當的醫學跟進。

禁忌症:

妊娠晚期，因為有動脈導管過早閉合和延長分娩的風險。

商標為赫力昂公司集團擁有或經授權使用。© 2022赫力昂公司集團或其授權人。

TECHNICAL INFORMATION

CUT	
AMENDMENTS	
1	NEW
2	
3	
DRAWING OWNER:	TRIDENT
MANUFACTURING SITE:	Interphil
DATE:	19/09/2022
LEAFLET	
PACK DIMENSIONS 145x210mm	
DRAWING NO: DL-leaflet 210mm x 145mm	V1 SCALE 1:1
APPROVED BY GSK:	<input type="checkbox"/> YES <input checked="" type="checkbox"/> NO Technical Drawing created by Trident

V1

Artwork Information Panel

HALEON

02 - Jan - 2024

Non Production Artwork

Production Artwork

Component No: AWP No:
PR-030197HKAA TR3080093/A

Total Number of Colours including Varnish & Foils: 1

Manufacturing Site:
Teh Seng
(Note: North American Artwork will have N/A in this field)

Approving Market:
Hong Kong

Technical Drawing No:
DL- leaflet 210mm x 145mm

Material Spec No:
NA
(Note: North American Artwork will have N/A in this field)

Body Text Size: 6.0pt
Smallest Text Size: 6.0pt
(Note: For smaller text sizes, please refer to the Artwork Specifications for more information)

Electronic Verification Code:
N/A

Total Special Finishes: 0

Printer and User notes:

Studio Location: Asia

AIP_CHAMPS_2023_HALEON

210mm x 145mm

— 刀線 CUTLINE

PR-030197HKAA

10mm

10mm